857264-71-2

Basic information

• Product Name: 2-chloro-N-(2,6-dihydroxyphenyl)acetamide
• Synonyms: 2-chloro-N-(2,6-dihydroxyphenyl)acetamide
• CAS NO: 857264-71-2
• Molecular Weight: 201.609
• Mol File: 857264-71-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-chloro-N-(2,6-dihydroxyphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(2,6-dihydroxyphenyl)acetamide(857264-71-2)
• EPA Substance Registry System: 2-chloro-N-(2,6-dihydroxyphenyl)acetamide(857264-71-2)

Safety Data

• Hazardous Substances Data: 857264-71-2(Hazardous Substances Data)

Upstream product

• 634-60-6 2-aminoresorcinol hydrochloride 
• 79-04-9 chloroacetyl chloride 
• 601-89-8 2-nitroresorcinol 

Downstream Products

• 177210-33-2 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one 

Relevant articles and documents

Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists

By means of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogates present in the β2-adrenoceptor agonists procaterol and BI-167107 (4), we designed and synthesized a collection of novel hydroxy-substituted heteroarylpiperazines and heteroarylhomopiperazines with high dopamine D2 receptor (D2R) affinity. In contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively mimicking those interactions of dopamine and the D2R that are crucial for an active state, leading to the recruitment of β-arrestin-2. Interestingly, some ligands show considerably lower intrinsic activity in guanine nucleotide exchange experiments at D2R and consequently represent biased agonists favoring β-arrestin-2 recruitment over canonical G protein activation. The ligands' agonistic properties are substantially driven by the presence of an endocyclic H-bond donor.

Production Method of Nitrogen-Containing Fused Ring Compounds

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Synthesis and Evaluation of 2-Pyridinone Derivatives as HIV-1-Specific Reverse Transcriptase Inhibitors. 2. Analogues of 3-Aminopyridin-2(1H)-one

A series of nonnulceoside 3-aminopyridin-2(1H)-one derivatives was synthesized and evaluated for HIV-1 RT inhibitory properties.Several analogs proved to be potent and highly selective antagonists with in vitro IC50 values as low as 19 nM in the enzyme assay using rC*dG as template*primer.Two compounds from this series, 3-amino>-5-ethyl-6-methylpyridin-2(1H)-one (34, L-697,639) and the corresponding 4,7-dichloro analogue (37, L-697,661) inhibited the spread of HIV-1 IIIb infection by 95percent in MT4 cell culture at concentrations of 25-50 nM and were selected for clinical trials as antiviral agents.